KaloBios crushed by more bad data
This article was originally published in Scrip
Executive Summary
San Francisco's KaloBios Pharmaceuticals has once again been left disappointed by negative data, this time for KB001-A, its monoclonal antibody fragment to treat Pseudomonas aeruginosa (Pa) lung infections in patients with cystic fibrosis. The company has decided to stop development of the drug on the back of the Phase II study results, leaving it with just one candidate in the clinic.